Rigel Pharmaceuticals, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

FAIR VALUE (Tables)

FAIR VALUE (Tables)

3 Months Ended

Mar. 31, 2022

Schedule of financial assets measured at fair value on a recurring basis

The table below summarizes the fair value of our cash equivalents and short-term investments measured at fair value on a recurring basis, and are categorized based upon the lowest level of significant input to the valuations (in thousands):


	Assets at Fair Value as of March 31, 2022
	Level 1		Level 2		Level 3		Total
Money market funds	$	12,363	$	—	$	—	$	12,363
US treasury bills		—		35,170		—		35,170
Government-sponsored enterprise securities		—		15,559		—		15,559
Corporate bonds and commercial paper		—		40,357		—		40,357
Total	$	12,363	$	91,086	$	—	$	103,449


	Assets at Fair Value as of December 31, 2021
	Level 1		Level 2		Level 3		Total
Money market funds	$	6,842	$	—	$	—	$	6,842
US treasury bills		—		35,366		—		35,366
Government-sponsored enterprise securities		—		14,678		—		14,678
Corporate bonds and commercial paper		—		61,832		—		61,832
Total	$	6,842	$	111,876	$	—	$	118,718